Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.

Ger Med Sci · 2014 · PMC4202665 · PMID 25332702

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, lixisenatide showed a trend towards better results compared with NPH-insulin with respect to confirmed hypoglycaemia (OR: 0.46; 95% CI: 0.22, 0.96; RR: 0.61; 95% CI: 0.33, 1.09), or a risk reduction of 39% (Table 4 (Tab. 4) ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.